"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic myelomonocytic leukemia presented at ESMO Congress 2024. Tremblay, an assistant professor ...

"The results from these studies represent a significant milestone for Solu, as they reinforce the potential of STX-0712 in the treatment CMML and AML, two diseases with limited targeted therapies ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Merin, director of the leukemia program at Cedars-Sinai ...

Funding to support clinical evaluation of STX-0712, drive additional pipeline programs, and target new applications of company's proprietary CyTAC™ and TicTAC™ platforms. Phase 1 trial of STX-0712 to ...

Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial PURPOSE: We report the first large prospective study of children ...

BOSTON, Dec. 2, 2024 /PRNewswire/ -- Solu Therapeutics ("Solu Therapeutics" or "Solu"), a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and ...